Sign in
4

Changes in Ownership

Ensysce Biosciences, Inc. Filed Acc 0001192482-21-000612

Options or other derivatives

  • Chief Commercial Officer acquired 349,005 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Birkett Kevin Geoffrey · Chief Commercial Officer

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2021-06-30 Grant or award : show line 1 in the form Stock Option +19,755 19,755 D
2021-06-30 Grant or award : show line 2 in the form Stock Option +329,250 329,250 D
Loading xslF345X03/edgar.xml…